Search
Luteci (177Lu) oxodotreotida per al tractament de tumors neuroendocrins gastroenteropancreàtics positius al receptor de somatostatina, ben diferenciats, progressius i irresecables o metastàtics
(2020-07-07)
Neuroendocrine tumors (TNEs) are defined as those neoplasms with a predominantly neuroendocrine cell differentiation, which can arise in most organs, although most are of gastrointestinal or pancreatic origin (≈65%). The ...
Tractament del CPNM metastàtic EFGR positiu amb inhibidors d’ITK en primera línia: informe d'avaluació de resultats
(2021)
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of new cases of LC for 2019 was 29,503 cases. LC remains the leading cause of cancer death in Spain in both ...
Durvalumab per al tractament del càncer de pulmó no microcític estadi III irresecable
(2020-03-25)
Non-microcytic lung cancer (CPNM) in stage III consists of a heterogeneous population with two subsets: stage IIIA and IIIB. Most patients with stage IIIA / B have an inoperable (non-resectable) disease. Only a third of ...
Tractament del CPNM metastàtic en primera i segona línia amb immunoteràpia: informe d'avaluació de resultats
(2021)
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of LC for 2019 was 29,503 new cases. LC remains the leading cause of cancer death in Spain in both sexes, with ...
Sorafenib i lenvatinib per al tractament en primera línia del carcinoma hepatocel·lular (CHC)
(2020-07-29)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, the fifth most common cancer in men and the seventh in women, and is associated with high mortality, which is the third leading cause of cancer death. ...
Pertuzumab en combinació amb trastuzumab i quimioteràpia per al tractament neoadjuvant de pacients adults amb càncer de mama HER2 positiu, localment avançat, inflamatori, o en estadi precoç amb alt risc de recaiguda: informe d'avaluació de resultats
(2020)
Breast cancer (BC) is the most common neoplasm in women and the leading cause of cancer death in European women. Pertuzumab is a monoclonal antibody that inhibits epidermal growth factor (HER2) receptor 2 dimerization. The ...